DBV Technologies screens first THRIVE participant
Analysis based on 6 articles · First reported Jun 02, 2026 · Last updated Jun 03, 2026
The announcement of the first participant screened in the THRIVE study for the VIASKIN Peanut Patch by DBV Technologies could positively impact the company's stock price, as it signifies progress in its clinical pipeline. Success in this trial could open a new market segment for early intervention in peanut allergy, benefiting DBV Technologies and the biotechnology industry.
DBV Technologies announced the screening of the first participant in its THRIVE Phase 2 clinical study for the VIASKIN Peanut Patch. This study evaluates the efficacy and safety of the patch in infants aged 6 to 12 months with peanut allergy, aiming for 'ad lib' consumption of dietary peanut. Douglas Mack, Assistant Clinical Professor at McMaster University, screened the first participant. Daniel Tassé, CEO of DBV Technologies, highlighted the importance of early, non-invasive intervention. The study involves daily patch application for 36 months, followed by a peanut food challenge to determine consumption regimens. This initiative builds on previous positive results in toddlers and children, expanding DBV Technologies' clinical program into a younger patient population.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard